24 May 2013 - R-Tech Ueno (JASDAQ:4573), a pharmaceutical venture business engaged in the Research and Development, manufacture and sale of drugs having high medical needs, has received approval from the FDA for its novel ophthalmic solution, RU-101, to enter into Phase I/II trials, it was reported yesterday.

The ophthalmic solution has been developed using Novozymes Biopharma's recombinant human albumin. It is to trial the ophthalmic solution as a severe dry eye therapy.

The first two stages of the studies will evaluate safety and confirm the maximum dose, which will then be assessed for safety and effectiveness for a 12-week period in the second stage.